ELVN — Enliven Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1672619 ·
Last close
$42.53
Market Cap
$2.59B
52W High
$48.53
52W Low
$26.70
ADV30
706,163
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,823,000 | -23,627,000 | 464,852,000 | 132,184,000 | 11,487,000 |
| Dec 2025 | 0 | — | -34,285,000 | -29,667,000 | 476,168,000 | 98,896,000 | 16,568,000 |
| Sep 2025 | 0 | — | -25,096,000 | -20,148,000 | 490,875,000 | 101,732,000 | 14,753,000 |
| Jun 2025 | 0 | — | -28,584,000 | -25,335,000 | 503,887,000 | 119,437,000 | 15,415,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-70,301,000
Investing CF
$-173,841,000
Financing CF
$218,867,000
CapEx
$-181,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-347,166,000
Inventory
—
Receivables
—
ST Investments
$363,725,000
EBIT TTM
$-119,658,000
Pretax Income TTM
$-103,694,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -119,658,000 | -103,694,000 | 476,168,000 | 16,568,000 | — | -70,301,000 |
| Dec 2024 | 0 | -104,554,000 | -89,024,000 | 325,760,000 | 15,915,000 | — | -73,192,000 |
| Dec 2023 | 0 | -83,529,000 | -71,584,000 | 271,867,000 | 25,961,000 | — | -61,269,000 |
| Dec 2022 | 0 | -38,791,000 | -37,662,000 | 83,298,000 | 160,123,000 | — | -32,077,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.38
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $2.58B | $29.35 | — |
| IRON | Disc Medicine, Inc. | $2.60B | $68.12 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $2.64B | $21.11 | — |
| IMNM | Immunome Inc. | $2.48B | $21.91 | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.47B | $29.99 | — |
News headlines (Yahoo Finance, 1h cache)
Enliven Therapeutics to Present at Upcoming Investor Conferences
2026-05-21 20:05 · Yahoo
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%
2026-05-13 21:06 · Yahoo
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
2026-05-12 13:53 · Yahoo
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026?
2026-05-10 23:13 · Yahoo
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
2026-05-07 20:05 · Yahoo
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market
2026-04-17 11:15 · Yahoo
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho
2026-04-06 21:09 · Yahoo
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum
2026-03-30 05:05 · Yahoo
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
2026-03-28 16:46 · Yahoo
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’
2026-03-26 00:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.